LRIG1 polyclonal antibody, anti-human, mouse

Background:
The LRRs and the Ig-domains are each sufficient for EGFR/ERBB1 binding. This interaction is abolished only when these two domains are deleted.,Act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation.,induction:By EGF.,Contains 17 LRR (leucine-rich) repeats.,Contains 3 Ig-like C2-type (immunoglobulin-like) domains.,subunit:Interacts with EGFR/ERBB1, ERBB2, ERBB3 and ERBB4.,tissue specificity:Widely expressed.,

Research Area: Cancer

Synonyms: Leucine-rich repeats and immunoglobulin-like domains protein 1 , LIG-1

Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration: 1 mg/ml

Storage:
-20°C for 1 year